Genmab A/S Banner Image

Genmab A/S

  • Ticker GMAB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Genmab A/S Logo Image
  • 501-1000 Employees
  • Based in Copenhagen, Denmark
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Their headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. They are the creators of three marketed products* and have a broad clinical andMore pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.
4.7 / 5.0 (141)

Genmab A/S reports have an aggregate usefulness score of 4.7 based on 141 reviews.

Genmab A/S

Most Recent Annual Report

Genmab A/S
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Genmab A/S Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!